1.Idiopathic airway-centered interstitial fibrosis: report of two cases.
Xiang-hua YI ; Hai-qing CHU ; Xiao-ming CHENG ; Ben-fang LUO ; Hui-ping LI
Chinese Medical Journal 2007;120(9):847-850
Adult
;
Diagnosis, Differential
;
Humans
;
Lung
;
pathology
;
Lung Diseases, Interstitial
;
diagnosis
;
drug therapy
;
pathology
;
Male
;
Middle Aged
2.A Good Outcome for a Case of Chronic Pneumonitis of Infancy.
Jong Min KIM ; Seung Yeon KWON ; Eun Soo KIM ; Myung Hyun SOHN ; Kyu Earn KIM ; Myung Joon KIM ; Sang Ho CHO
Yonsei Medical Journal 2007;48(5):865-867
Chronic pneumonitis of infancy (CPI) is a very rare interstitial lung disease. Its pathological features differ from other types of interstitial pneumonia that occur in adults and children. The mortality rate of CPI is high, even with treatment. We report a case of a 3 month old girl diagnosed with CPI after an open lung biopsy who improved after proper treatment.
Biopsy
;
Female
;
Humans
;
Infant
;
Lung Diseases, Interstitial/*diagnosis/drug therapy/pathology
;
Pneumonia/*diagnosis/drug therapy/pathology
;
Tomography, X-Ray Computed
3.Pathology of Chronic Interstitial Lung Disease.
Korean Journal of Pathology 1998;32(1):1-8
Interstitial lung disease is a generic term for a heterogeneous group of lung disease that primarily affect the interstitium although the disease is not clearly restricted to the interstitium. The majority of interstitial lung diseases represent inflammatory insults to the microscopic anatomic space bounded by the basement membrane of epithelial and endothelial cells, which may occur as slowly developing process and ultimately end up as end-stage honeycomb fibrosis. The currently prevalent classification of interstitial pneumonia with practical utility and easy reproducibility pertaining only to idopathic interstitial pneumonia encompasses several different entities some of which may represent different aspects of the same condition. Honeycomb fibrosis is usually caused by a variety of pulmonary disease including chronic interstitial lung disease. It is important to recognize that usual inter-stitial pneumonia and honeycomb fibrosis are not synonymous. In the era of chemotherapy for malignant tumor, aggressive immunosuppression for autoimmune diseases and transplant recipients and acquired immunodeficiency syndrome, lung disease in the immunocompromised host has been common. Diagnostic lung biopsy becomes increasingly needed because proper treatment of interstitial lung disease relies on correct morphologic diagnosis. This review summarizes the pathologic spectrum of idiopathic interstitial pneumonias together with other inflammatory process with known or suggestive etiologies simulating interstitial pneumonias.
Acquired Immunodeficiency Syndrome
;
Autoimmune Diseases
;
Basement Membrane
;
Biopsy
;
Classification
;
Diagnosis
;
Drug Therapy
;
Endothelial Cells
;
Fibrosis
;
Idiopathic Interstitial Pneumonias
;
Immunocompromised Host
;
Immunosuppression
;
Lung
;
Lung Diseases
;
Lung Diseases, Interstitial*
;
Pathology*
;
Pneumonia
;
Transplantation
4.A case of neuroendocrine cell hyperplasia of infancy (NEHI).
Liyuan LYU ; Xiuyun LIU ; Zaifang JIANG
Chinese Journal of Pediatrics 2014;52(4):317-318
Acetates
;
therapeutic use
;
Diagnosis, Differential
;
Female
;
Follow-Up Studies
;
Humans
;
Hyperplasia
;
Infant
;
Lung
;
diagnostic imaging
;
pathology
;
physiopathology
;
Lung Diseases, Interstitial
;
diagnosis
;
drug therapy
;
physiopathology
;
Methylprednisolone
;
therapeutic use
;
Neuroendocrine Cells
;
pathology
;
Quinolines
;
therapeutic use
;
Tomography, X-Ray Computed
5.Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection.
Na Ri LEE ; Ji Won JANG ; Hee Sun KIM ; Ho Young YHIM
The Korean Journal of Internal Medicine 2015;30(4):550-553
No abstract available.
Adult
;
Antineoplastic Agents/*adverse effects
;
Antitubercular Agents/therapeutic use
;
Biopsy
;
Female
;
Gastrointestinal Stromal Tumors/*drug therapy/pathology/surgery
;
Humans
;
Imatinib Mesylate/*adverse effects
;
Lung Diseases, Interstitial/*chemically induced/diagnosis
;
Mycobacterium tuberculosis/*isolation & purification
;
Protein Kinase Inhibitors/*adverse effects
;
Rectal Neoplasms/*drug therapy/pathology/surgery
;
Tomography, X-Ray Computed
;
Tuberculosis, Pulmonary/diagnosis/drug therapy/*microbiology
6.Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease.
Li CHEN ; Yan HU ; Yuan YAO ; Xiao-fang ZHEN ; Fang CHEN ; Qiang HE ; Xin MO ; Song-Chun MA
Chinese Journal of Pediatrics 2012;50(6):465-469
OBJECTIVETo explore the clinical and laboratory features and the prognosis of juvenile dermatomyositis (JDM) complicated with interstitial lung disease (ILD).
METHODData of 39 cases of JDM complicated with ILD hospitalized in Beijing Children's Hospital from January 2005 to December 2011 were collected. The clinical features, laboratory data and prognosis of these children were analyzed.
RESULTOf the 39 cases studied, 16 were boys, and 23 girls. The average age of onset was 5.6 years, and 61.5% of the patients' age of onset (24 cases) was under 6 years. Rashes (17 cases, 43.6%), simultaneous eruption of rashes and muscle weakness (14 cases, 35.9%), fever (4 cases, 10.1%), or muscle weakness (3 cases, 7.7%) were common initial symptoms of the disease. Only 51.3% of the patients (20 cases) had the symptoms of respiratory system, but (24 cases) 61.5% were complicated with that of the gastrointestinal system; (27 cases) 69.2% had at the same time electrocardiographic and echocardiographic abnormalities. The chest high resolution computed tomography (HRCT) showed cord or band-like shadows in their lungs of more than half of the cases (25 cases, 64.1%), and other changes included ground glass-like shadow (10 cases, 25.6%), net and lineation-like shadow (9 cases, 23.1%), nodular change (5 cases, 12.8%). The patients complicated with lung essential infiltration accounted for as high as 71.8% (28 cases). These imaging changes were largely seen on both dorsal sides of their lungs. Severe patients also had mediastinal emphysema, pneumothorax, pneumorrhagia or aerodermectasia. Twenty-four patients underwent pulmonary function examination, and 62.5% of the patients' pulmonary function (15 cases) was abnormal. The fatality rate of the cases studied was 10.1%.
CONCLUSIONThe imaging changes of patients suffering from JDM with ILD were often more severe as compared to the clinical symptoms, and were often complicated with damages to other systems and organs. The prognosis of those patients was poorer than others. Patients with JDM especially at a younger age of onset and with various organ damages should be examined with chest HRCT examinations as early as possible.
Child ; Child, Preschool ; Dermatomyositis ; complications ; diagnosis ; drug therapy ; Female ; Glucocorticoids ; administration & dosage ; therapeutic use ; Humans ; Immunosuppressive Agents ; administration & dosage ; therapeutic use ; Lung ; diagnostic imaging ; pathology ; Lung Diseases, Interstitial ; diagnosis ; drug therapy ; etiology ; Male ; Methotrexate ; administration & dosage ; therapeutic use ; Muscle Weakness ; diagnosis ; epidemiology ; etiology ; Prognosis ; Respiratory Function Tests ; Retrospective Studies ; Tomography, X-Ray Computed
7.A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab.
Tomoaki HIGUCHI ; Takashi NAKANISHI ; Kunio TAKADA ; Mitsuyo MATSUMOTO ; Makoto OKADA ; Hideyuki HORIKOSHI ; Kimihiro SUZUKI
Journal of Korean Medical Science 2010;25(9):1364-1367
This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old female with abnormal shadows on a chest X-ray was referred to the hospital for further examination. She was diagnosed as having MCD based on the characteristic pathology of inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may therefore be a beneficial treatment regimen for lung lesions associated with MCD.
Adrenal Cortex Hormones/therapeutic use
;
Adult
;
Antibodies, Monoclonal/*therapeutic use
;
Drug Therapy, Combination
;
Female
;
Giant Lymph Node Hyperplasia/*diagnosis/drug therapy/radiography
;
Humans
;
Immunosuppressive Agents/therapeutic use
;
Lung Diseases, Interstitial/*drug therapy/pathology
;
Lymph Nodes/pathology
;
Receptors, Interleukin-6/antagonists & inhibitors
;
Tacrolimus/therapeutic use
;
Tomography, X-Ray Computed